Method for treating allergic dermatitis
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-7906149-B2
Publication Date
2011-03-15
Expiration Date
Abstract
A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.
Core Innovation
The invention relates to a method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a composition comprising albumin at a therapeutically effective amount for a sufficient amount of time to enable the albumin to provide a localized anti-inflammatory effect, and then removing the albumin from the affected area. The method minimizes the removal of protective lipids from the skin during removal of the albumin.
The composition removes oleoresin toxins from dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states. The binding occurs with oleoresin toxins associated with dermal proteins, and the topical effect is described as localized anti-inflammatory.
Oleoresin induced allergic dermatitis includes cases involving urushiol and/or isosolenopsin A as the oleoresin toxins. The disclosed treatments include albumin-containing compositions in multiple forms, and the compositions are characterized functionally by both minimizing removal of protective skin lipids and removing oleoresin toxins from dermal proteins via binding in native and oxidized states.
Claims Coverage
The independent claims cover five ways of treating oleoresin induced allergic dermatitis, each centered on topical contact with an albumin-containing composition followed by removal, and characterized by localized anti-inflammatory effect and binding of oleoresin toxins in both native and oxidized states while minimizing removal of protective skin lipids.
Albumin topical contacting with localized anti-inflammatory effect and binding in native and oxidized states
Topically contacting an affected area with a composition consisting essentially of from about 2 to about 6 percent by weight of albumin for a sufficient amount of time to enable the albumin to provide a localized anti-inflammatory effect and removing the albumin from the affected area, wherein the composition minimizes the removal of protective lipids from the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Specified multi-component composition for topical contacting and removal
Topically contacting an affected area with a composition consisting of by weight from 2 to 6% of albumin, from 0.05 to 0.1% of a chelating agent, from 0.05 to 0.1% of a preservative, from 0.5 to 2% of a thickener, from 2 to 6% of a co-solvent, from 1.0 to 4.0% of an humectant, and a diluent, and removing the composition from the affected area, wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Bovine serum albumin multi-component topical contacting and removal
Topically contacting an affected area with a composition consisting of by weight from 2 to 6% of a bovine serum albumin, from 0.05 to 0.1% of a chelating agent, from 0.05 to 0.1% of a preservative, from 0.5 to 2% of a thickener, from 2 to 6% of a co-solvent, from 1.0 to 4.0% of an humectant, and a diluent, and removing the composition from the affected area, wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Specified albumin excipient set with water for topical contacting and removal
Topically contacting an affected area with a composition consisting of by weight from 2 to 6% of albumin, from 0.05 to 0.1% of disodium ethylenediamine tetraacetate, from 0.05 to 0.1% of methyl paraben, from 0.5 to 2% of hydroxypropylcellulose, from 2 to 6% of polyethylene glycol, from 1.0 to 4.0% of glycerine, and water, and removing the composition from the affected area, wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Bovine serum albumin with specified excipients and water for topical contacting and removal
Topically contacting an affected area with a composition consisting of by weight from 2 to 6% of bovine serum albumin, from 0.05 to 0.1% of disodium ethylenediamine tetraacetate, from 0.05 to 0.1% of methyl paraben, from 0.5 to 2% of hydroxypropylcellulose, from 2 to 6% of polyethylene glycol, from 1.0 to 4.0% of glycerine, and water, and removing the composition from the affected area, wherein the composition minimizes the removal of protective lipids of the skin and removes oleoresin toxins from the dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Across the independent claims, the coverage is unified by topical contacting of an affected area with an albumin-containing composition, a removal step, and functional requirements that the composition minimizes removal of protective skin lipids while removing oleoresin toxins from dermal proteins by binding to oleoresin toxins in both native and oxidized states, with albumin providing a localized anti-inflammatory effect.
Stated Advantages
Provides a localized anti-inflammatory effect.
Minimizes the removal of protective lipids from the skin.
Removes oleoresin toxins from dermal proteins of the skin by binding to oleoresin toxins in both native and oxidized states.
Documented Applications
Treating oleoresin induced allergic dermatitis, including dermatitis associated with urushiol and/or isosolenopsin A.
Interested in licensing this patent?